Julien Mayaux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julien Mayaux has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Elie Azoulay
Service de médecine intensive et réanimation, Hôpital Saint-Louis, Assistance Publique Des Hôpitaux de Paris, Paris, France
6 shared publications - Charles-Edouard Luyt
Médecine Intensive Réanimation, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France
5 shared publications - Frédéric Pène
Assistance Publique – Hôpitaux de Paris, Service de Médecine Intensive-Réanimation, Medical Intensive Care Unit, Hôpital Cochin, Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France
5 shared publications - Virginie Lemiale
AP-HP Saint-Louis, Intensive Care Unit, Paris, France
5 shared publications - Achille Kouatchet
Service de Réanimation Médicale et Médecine Hyperbare, Centre Hospitalier Régional Universitaire, 49100 Angers, France
4 shared publications - Alexandre Demoule
INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France
4 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (9) , 652
Invasive Aspergillosis Complicating Severe COVID-19: Cumulative Incidence, Risk Factors, and Outcomes Between the First Wave of the Pandemic and Subsequent Waves, According to the ECMM/ISHAM Classification and a Local Case Assessment
The role of severe COVID-19 as an independent risk factor for invasive aspergillosis remains debated, with reported incidences varying widely across studies. We compared the cumulative incidence, risk factors, and outcomes of invasive pulmonary mold infection (IPMI) in intensive care unit patients with confirmed COVID-19 during the first epidemic wave and subsequent waves up to March 2021 at La Pitié-Salpêtrière Hospital, Paris, France. Patients were systematically screened for fungal infections and classified according to ECMM/ISHAM criteria and a more stringent local assessment. The study included 259 patients (n = 171, first wave and n = 88, subsequent waves). Patient characteristics were similar between periods, although short-course corticosteroid therapy increased over time. Mortality rates remained unchanged. Cumulative incidence of IPMI did not differ significantly between waves, regardless of the classification system used: 12.1% versus 15.1% with ECMM/ISHAM criteria and 4.2% versus 5.8% with local assessment. IPMI was associated with solid organ transplantation and pre-existing long-term corticosteroid therapy, whereas short-course corticosteroid therapy for COVID-19 was not associated with increased risk. IPMI was strongly associated with 90-day mortality. Classification as probable COVID-19-Associated Pulmonary Aspergillosis using the ECMM/ISHAM criteria may be partly influenced by the number of diagnostic samples collected. Overall, our findings underline that the classification system substantially influences both incidence estimates and the interpretation of survival outcomes.
- 1 September 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (9) , 652
Open AccessInvasive Aspergillosis Complicating Severe COVID-19: Cumulative Incidence, Risk Factors, and Outcomes Between the First Wave of the Pandemic and Subsequent Waves, According to the ECMM/ISHAM Classification and a Local Case Assessment
The role of severe COVID-19 as an independent risk factor for invasive aspergillosis remains debated, with reported incidences varying widely across studies. We compared the cumulative incidence, risk factors, and outcomes of invasive pulmonary mold infection (IPMI) in intensive care unit patients with confirmed COVID-19 during the first epidemic wave and subsequent waves up to March 2021 at La Pitié-Salpêtrière Hospital, Paris, France. Patients were systematically screened for fungal infections and classified according to ECMM/ISHAM criteria and a more stringent local assessment. The study included 259 patients (n = 171, first wave and n = 88, subsequent waves). Patient characteristics were similar between periods, although short-course corticosteroid therapy increased over time. Mortality rates remained unchanged. Cumulative incidence of IPMI did not differ significantly between waves, regardless of the classification system used: 12.1% versus 15.1% with ECMM/ISHAM criteria and 4.2% versus 5.8% with local assessment. IPMI was associated with solid organ transplantation and pre-existing long-term corticosteroid therapy, whereas short-course corticosteroid therapy for COVID-19 was not associated with increased risk. IPMI was strongly associated with 90-day mortality. Classification as probable COVID-19-Associated Pulmonary Aspergillosis using the ECMM/ISHAM criteria may be partly influenced by the number of diagnostic samples collected. Overall, our findings underline that the classification system substantially influences both incidence estimates and the interpretation of survival outcomes.
- 2 January 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (1) , 1-17
Cerebral oxygen saturation in cirrhotic patients with gastro-intestinal bleeding, a near infrared spectroscopy study
Near Infrared Spectroscopy (NIRS) is a non-invasive optical technique allowing a continuous measurement of brain’s hemoglobin (Hb) saturation in oxygen (rSO2). It is a marker of cerebral insult and rSO2 < 50% is associated with increased neurological impairment. Cirrhotic patients with gastrointestinal bleeding (GIB) often develop hepatic encephalopathy (HE). The aims of this study were: (1) to assess brain oxygenation using NIRS in cirrhotic patients with GIB, (2) to determine if brain oxygenation was correlated to Hb level, blood pressure and liver function (3) if brain oxygenation was influencing the occurrence of HE and survival. Cirrhotic patients admitted to ICU for GIB were prospectively included and compared to non-cirrhotic patients. Bilateral recording of rSO2 was started upon admission using an INVOS 5100c Cerebral Oxymeter (Covidien). Initial, minimal, average rSO2 and AUC of rSO2 < 50% (AUC50% rSO2) were extracted. Sixty-one cirrhotic and 14 non-cirrhotic patients were included. Child-Pugh score was at 9.5 ± 0.3 and MELD score was 17.8 ± 0.9. None of the NIRS parameters differed between cirrhotic and non-cirrhotic patients. Thirty-nine patients (64%) among the 61 cirrhotic and 10 (71%) among the 14 non-cirrhotic patients displayed an initial rSO2 below the 50% threshold at least on one side. NIRS parameters correlated mainly with Hb level and MELD but not with MAP or PaO2. There was no significant correlation between NIRS parameters and survival or HE upon admission, within 5 days and after discharge. Patients with GIB frequently present rSO2 below the threshold of 50%. The significance of this finding is uncertain since it does not seem clearly correlated to a poor outcome in ICU or in the follow-up.
- 2 January 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (1) , 1-17
Cerebral oxygen saturation in cirrhotic patients with gastro-intestinal bleeding, a near infrared spectroscopy study
Near Infrared Spectroscopy (NIRS) is a non-invasive optical technique allowing a continuous measurement of brain’s hemoglobin (Hb) saturation in oxygen (rSO2). It is a marker of cerebral insult and rSO2 < 50% is associated with increased neurological impairment. Cirrhotic patients with gastrointestinal bleeding (GIB) often develop hepatic encephalopathy (HE). The aims of this study were: (1) to assess brain oxygenation using NIRS in cirrhotic patients with GIB, (2) to determine if brain oxygenation was correlated to Hb level, blood pressure and liver function (3) if brain oxygenation was influencing the occurrence of HE and survival. Cirrhotic patients admitted to ICU for GIB were prospectively included and compared to non-cirrhotic patients. Bilateral recording of rSO2 was started upon admission using an INVOS 5100c Cerebral Oxymeter (Covidien). Initial, minimal, average rSO2 and AUC of rSO2 < 50% (AUC50% rSO2) were extracted. Sixty-one cirrhotic and 14 non-cirrhotic patients were included. Child-Pugh score was at 9.5 ± 0.3 and MELD score was 17.8 ± 0.9. None of the NIRS parameters differed between cirrhotic and non-cirrhotic patients. Thirty-nine patients (64%) among the 61 cirrhotic and 10 (71%) among the 14 non-cirrhotic patients displayed an initial rSO2 below the 50% threshold at least on one side. NIRS parameters correlated mainly with Hb level and MELD but not with MAP or PaO2. There was no significant correlation between NIRS parameters and survival or HE upon admission, within 5 days and after discharge. Patients with GIB frequently present rSO2 below the threshold of 50%. The significance of this finding is uncertain since it does not seem clearly correlated to a poor outcome in ICU or in the follow-up.
- 11 April 2024
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 41 (5) , 382-389
Ventilation non invasive dans l’insuffisance respiratoire aiguë des patients d’onco-hématologie : quelle place en 2023 ?
- 11 April 2024
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 41 (5) , 382-389
Ventilation non invasive dans l’insuffisance respiratoire aiguë des patients d’onco-hématologie : quelle place en 2023 ?
- Open Access
SARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study
The SARS-CoV-2 variant of concern, α, spread worldwide at the beginning of 2021. It was suggested that this variant was associated with a higher risk of mortality than other variants. We aimed to characterize the genetic diversity of SARS-CoV-2 variants isolated from patients with severe COVID-19 and unravel the relationships between specific viral mutations/mutational patterns and clinical outcomes. This is a prospective multicenter observational cohort study. Patients aged ≥18 years admitted to 11 intensive care units (ICUs) in hospitals in the Greater Paris area for SARS-CoV-2 infection and acute respiratory failure between 1 October 2020 and 30 May 2021 were included. The primary clinical endpoint was day-28 mortality. Full-length SARS-CoV-2 genomes were sequenced by means of next-generation sequencing (Illumina COVIDSeq). In total, 413 patients were included, 183 (44.3%) were infected with pre-existing variants, 197 (47.7%) were infected with variant α, and 33 (8.0%) were infected with other variants. The patients infected with pre-existing variants were significantly older (64.9 ± 11.9 vs. 60.5 ± 11.8 years; p = 0.0005) and had more frequent COPD (11.5% vs. 4.1%; p = 0.009) and higher SOFA scores (4 [3–8] vs. 3 [2–4]; 0.0002). The day-28 mortality was no different between the patients infected with pre-existing, α, or other variants (31.1% vs. 26.2% vs. 30.3%; p = 0.550). There was no association between day-28 mortality and specific variants or the presence of specific mutations. At ICU admission, the patients infected with pre-existing variants had a different clinical presentation from those infected with variant α, but mortality did not differ between these groups. There was no association between specific variants or SARS-CoV-2 genome mutational pattern and day-28 mortality.
Open AccessSARS-CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study
The SARS-CoV-2 variant of concern, α, spread worldwide at the beginning of 2021. It was suggested that this variant was associated with a higher risk of mortality than other variants. We aimed to characterize the genetic diversity of SARS-CoV-2 variants isolated from patients with severe COVID-19 and unravel the relationships between specific viral mutations/mutational patterns and clinical outcomes. This is a prospective multicenter observational cohort study. Patients aged ≥18 years admitted to 11 intensive care units (ICUs) in hospitals in the Greater Paris area for SARS-CoV-2 infection and acute respiratory failure between 1 October 2020 and 30 May 2021 were included. The primary clinical endpoint was day-28 mortality. Full-length SARS-CoV-2 genomes were sequenced by means of next-generation sequencing (Illumina COVIDSeq). In total, 413 patients were included, 183 (44.3%) were infected with pre-existing variants, 197 (47.7%) were infected with variant α, and 33 (8.0%) were infected with other variants. The patients infected with pre-existing variants were significantly older (64.9 ± 11.9 vs. 60.5 ± 11.8 years; p = 0.0005) and had more frequent COPD (11.5% vs. 4.1%; p = 0.009) and higher SOFA scores (4 [3–8] vs. 3 [2–4]; 0.0002). The day-28 mortality was no different between the patients infected with pre-existing, α, or other variants (31.1% vs. 26.2% vs. 30.3%; p = 0.550). There was no association between day-28 mortality and specific variants or the presence of specific mutations. At ICU admission, the patients infected with pre-existing variants had a different clinical presentation from those infected with variant α, but mortality did not differ between these groups. There was no association between specific variants or SARS-CoV-2 genome mutational pattern and day-28 mortality.
- Open Access
- 28 June 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (7) , 678
Occurrence of Candidemia in Patients with COVID-19 Admitted to Five ICUs in France
Whether severe COVID-19 is by itself a significant risk factor for the development of candidemia currently remains an open question as conflicting results have been published. We aim to assess the occurrence of candidemia in patients with severe COVID-19 admitted to the intensive care unit (ICU). We conducted a retrospective study on patients with severe SARS-CoV-2-related pneumonia admitted to 5 ICUs in France who were specifically screened for fungal complications between March 2020 and January 2021. The study population included a total of 264 patients; the median age was 56 years old and most of them were male (n = 186; 70.5%) and immunocompetent (n = 225; 87.5%), and 62.7% (n = 153/244) were on extracorporeal membrane oxygenation support. Microbiological analysis included 4864 blood culture samples and beta-glucan test performed on 975 sera. Candidemia was diagnosed in 13 (4.9%) patients. The species involved were mainly C. albicans (n = 6) and C. parapsilosis (n = 5). Almost all patients (12/13; 92.3%) had a colonization by yeasts. ICU mortality was not significantly impacted by the occurrence of candidemia. Unrelated positive beta-glucan tests were observed in 49 patients (23.4%), including 6 with mold infections and 43 with false positive results. In our series, patients with severe SARS-CoV-2-related pneumonia seemed at low risk of developing invasive candidiasis.
- 28 June 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (7) , 678
Open AccessOccurrence of Candidemia in Patients with COVID-19 Admitted to Five ICUs in France
Whether severe COVID-19 is by itself a significant risk factor for the development of candidemia currently remains an open question as conflicting results have been published. We aim to assess the occurrence of candidemia in patients with severe COVID-19 admitted to the intensive care unit (ICU). We conducted a retrospective study on patients with severe SARS-CoV-2-related pneumonia admitted to 5 ICUs in France who were specifically screened for fungal complications between March 2020 and January 2021. The study population included a total of 264 patients; the median age was 56 years old and most of them were male (n = 186; 70.5%) and immunocompetent (n = 225; 87.5%), and 62.7% (n = 153/244) were on extracorporeal membrane oxygenation support. Microbiological analysis included 4864 blood culture samples and beta-glucan test performed on 975 sera. Candidemia was diagnosed in 13 (4.9%) patients. The species involved were mainly C. albicans (n = 6) and C. parapsilosis (n = 5). Almost all patients (12/13; 92.3%) had a colonization by yeasts. ICU mortality was not significantly impacted by the occurrence of candidemia. Unrelated positive beta-glucan tests were observed in 49 patients (23.4%), including 6 with mold infections and 43 with false positive results. In our series, patients with severe SARS-CoV-2-related pneumonia seemed at low risk of developing invasive candidiasis.
- Open Access
- 28 February 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 550
Therapeutic Treatment Plan Optimization during the COVID-19 Pandemic: A Comprehensive Physicochemical Compatibility Study of Intensive Care Units Selected Drugs
Background: The SARS-CoV-2 pandemic has resulted in a dramatic rise of the demand for medical devices and drugs. In this context, an important shortage of programmable syringe pumps, used to administrate different drugs in intensive care units, was seen. The opportunity of administrating combinations of five intensive care units selected drugs (Sufentanil, Clonidine, Loxapine, Midazolam, and Ketamine) was considered. Methods: The drug mixtures were studied in a pure form or diluted in NaCl 0.9% or G5%. Twenty-six possible combinations of the five drugs were produced in glass vials or polypropylene syringes and stored at 25 °C for 14 days. The LC method was implemented to study drugs combinations in the presence of the degradation products. The clearness and pH were also monitored. Results: All the 26 possible combinations displayed adequate physicochemical stability at 25 °C: at least 3 days and 7 days, respectively, for the dilution in 0.9% NaCl or glucose 5%, and the pure drug products mixtures. Conclusions: The study provided sufficient stability results, covering the medication administration period of at least three days. The combination of more than two drugs offers the advantage of minimizing the individual doses and reduces unwanted side-effects. Hence, this study opens up the possibility of combining the five drugs in one single syringe, which is useful especially under the current circumstances associated with an important shortage of programmable syringe pumps and pharmaceuticals.
- 28 February 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 550
Open AccessTherapeutic Treatment Plan Optimization during the COVID-19 Pandemic: A Comprehensive Physicochemical Compatibility Study of Intensive Care Units Selected Drugs
Background: The SARS-CoV-2 pandemic has resulted in a dramatic rise of the demand for medical devices and drugs. In this context, an important shortage of programmable syringe pumps, used to administrate different drugs in intensive care units, was seen. The opportunity of administrating combinations of five intensive care units selected drugs (Sufentanil, Clonidine, Loxapine, Midazolam, and Ketamine) was considered. Methods: The drug mixtures were studied in a pure form or diluted in NaCl 0.9% or G5%. Twenty-six possible combinations of the five drugs were produced in glass vials or polypropylene syringes and stored at 25 °C for 14 days. The LC method was implemented to study drugs combinations in the presence of the degradation products. The clearness and pH were also monitored. Results: All the 26 possible combinations displayed adequate physicochemical stability at 25 °C: at least 3 days and 7 days, respectively, for the dilution in 0.9% NaCl or glucose 5%, and the pure drug products mixtures. Conclusions: The study provided sufficient stability results, covering the medication administration period of at least three days. The combination of more than two drugs offers the advantage of minimizing the individual doses and reduces unwanted side-effects. Hence, this study opens up the possibility of combining the five drugs in one single syringe, which is useful especially under the current circumstances associated with an important shortage of programmable syringe pumps and pharmaceuticals.
- Open Access
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
Background: Since 1920, a decrease in serum cholesterol has been identified as a marker of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the main transporter of HDL-cholesterol, to identify the early spread of coronavirus disease 2019 (Covid-19) in the general population and its diagnostic performance for the Covid-19. Methods: We compared the daily mean serum apolipoprotein-A1 during the first 30 weeks of 2020 in a population that is routinely followed for a risk of liver fibrosis risk in the USA (183,112 sera) and in France (18,316 sera) in relation to a local increase in confirmed cases, and in comparison to the same period in 2019 (respectively 234,881 and 26,056 sera). We prospectively assessed the sensitivity of this marker in an observational study of 136 consecutive hospitalized cases and retrospectively evaluated its specificity in 7,481 controls representing the general population. Results: The mean serum apolipoprotein-A1 levels in these populations began decreasing in January 2020, compared to the same 30 weeks in 2019. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases in the following 30 weeks, in both France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-A1 at the 1.25 g/L cutoff had a sensitivity of 90.6% (95%CI84.2-95.1) and a specificity of 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk ratio for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0;P=0.04). Conclusion: Apolipoprotein-A1 could be both a sentinel of the pandemic in existing routine surveillance of the general population with no new blood sample, as well as a candidate predictor of suspected Covid-19 in multivariate analysis in cases with a negative virological test. NCT01927133 , CER-2020-14. Key Points: Question: Does serum apolipoprotein-A1 decrease could be a very early biomarker of SARS-CoV-2 pandemic? Findings: During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous years. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases, including the recovery period. Meaning: Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine surveillance of the general population.
Open AccessPerformance of serum apolipoprotein-A1 as a sentinel of Covid-19
Background: Since 1920, a decrease in serum cholesterol has been identified as a marker of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the main transporter of HDL-cholesterol, to identify the early spread of coronavirus disease 2019 (Covid-19) in the general population and its diagnostic performance for the Covid-19. Methods: We compared the daily mean serum apolipoprotein-A1 during the first 30 weeks of 2020 in a population that is routinely followed for a risk of liver fibrosis risk in the USA (183,112 sera) and in France (18,316 sera) in relation to a local increase in confirmed cases, and in comparison to the same period in 2019 (respectively 234,881 and 26,056 sera). We prospectively assessed the sensitivity of this marker in an observational study of 136 consecutive hospitalized cases and retrospectively evaluated its specificity in 7,481 controls representing the general population. Results: The mean serum apolipoprotein-A1 levels in these populations began decreasing in January 2020, compared to the same 30 weeks in 2019. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases in the following 30 weeks, in both France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-A1 at the 1.25 g/L cutoff had a sensitivity of 90.6% (95%CI84.2-95.1) and a specificity of 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk ratio for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0;P=0.04). Conclusion: Apolipoprotein-A1 could be both a sentinel of the pandemic in existing routine surveillance of the general population with no new blood sample, as well as a candidate predictor of suspected Covid-19 in multivariate analysis in cases with a negative virological test. NCT01927133 , CER-2020-14. Key Points: Question: Does serum apolipoprotein-A1 decrease could be a very early biomarker of SARS-CoV-2 pandemic? Findings: During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous years. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases, including the recovery period. Meaning: Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine surveillance of the general population.
- Open Access
IgA dominates the early neutralizing antibody response to SARS-CoV-2
A major dogma in immunology has it that the IgM antibody response precedes secondary memory responses built on the production of IgG, IgA and, occasionaly, IgE. Here, we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of specific, neutralizing, antibodies in serum and broncho-alveolar fluid of 145 patients with COVID-19. Surprisingly, early SARS-CoV-2-specific humoral responses were found to be typically dominated by antibodies of the IgA isotype. Peripheral expansion of IgA-plasmablasts with mucosal-homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. While the specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization, as compared to IgG. However, specific IgA serum levels notably decrease after one month of evolution. These results represent a challenging observation given the present uncertainty as to which kind of humoral response would optimally protect against re-infection, and whether vaccine regimens should consider boosting a potent, although, at least in blood, fading IgA response. One sentence Summary: While early specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization.
Open AccessIgA dominates the early neutralizing antibody response to SARS-CoV-2
A major dogma in immunology has it that the IgM antibody response precedes secondary memory responses built on the production of IgG, IgA and, occasionaly, IgE. Here, we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of specific, neutralizing, antibodies in serum and broncho-alveolar fluid of 145 patients with COVID-19. Surprisingly, early SARS-CoV-2-specific humoral responses were found to be typically dominated by antibodies of the IgA isotype. Peripheral expansion of IgA-plasmablasts with mucosal-homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. While the specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization, as compared to IgG. However, specific IgA serum levels notably decrease after one month of evolution. These results represent a challenging observation given the present uncertainty as to which kind of humoral response would optimally protect against re-infection, and whether vaccine regimens should consider boosting a potent, although, at least in blood, fading IgA response. One sentence Summary: While early specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization.
- Open Access
- 16 December 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-10
The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial
Background: The Artificial Kidney Initiation in Kidney Injury (AKIKI) trial showed that a delayed renal replacement therapy (RRT) strategy for severe acute kidney injury (AKI) in critically ill patients was safe and associated with major reduction in RRT initiation compared with an early strategy. The five criteria which mandated RRT initiation in the delayed arm were: severe hyperkalemia, severe acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration > 40 mmol/l and oliguria/anuria > 72 h. However, duration of anuria/oliguria and level of blood urea are still criteria open to debate. The objective of the study is to compare the delayed strategy used in AKIKI (now termed “standard”) with another in which RRT is further delayed for a longer period (termed “delayed strategy”). Methods/design: This is a prospective, multicenter, open-label, two-arm randomized trial. The study is composed of two stages (observational and randomization stages). At any time, the occurrence of a potentially severe condition (severe hyperkalemia, severe metabolic or mixed acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia) suggests immediate RRT initiation. Patients receiving (or who have received) intravenously administered catecholamines and/or invasive mechanical ventilation and presenting with AKI stage 3 of the KDIGO classification and with no potentially severe condition are included in the observational stage. Patients presenting a serum urea concentration > 40 mmol/l and/or an oliguria/anuria for more than 72 h are randomly allocated to a standard (RRT is initiated within 12 h) or a delayed RRT strategy (RRT is initiated only if an above-mentioned potentially severe condition occurs or if the serum urea concentration reaches 50 mmol/l). The primary outcome will be the number of RRT-free days at day 28. One interim analysis is planned. It is expected to include 810 patients in the observational stage and to randomize 270 subjects. Discussion: The AKIKI2 study should improve the knowledge of RRT initiation criteria in critically ill patients. The potential reduction in RRT use allowed by a delayed RRT strategy might be associated with less invasive care and decreased costs. Enrollment is ongoing. Inclusions are expected to be completed by November 2019. Trial registration: ClinicalTrials.gov, ID: NCT03396757. Registered on 11 January 2018.
- 16 December 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-10
Open AccessThe Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial
Background: The Artificial Kidney Initiation in Kidney Injury (AKIKI) trial showed that a delayed renal replacement therapy (RRT) strategy for severe acute kidney injury (AKI) in critically ill patients was safe and associated with major reduction in RRT initiation compared with an early strategy. The five criteria which mandated RRT initiation in the delayed arm were: severe hyperkalemia, severe acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration > 40 mmol/l and oliguria/anuria > 72 h. However, duration of anuria/oliguria and level of blood urea are still criteria open to debate. The objective of the study is to compare the delayed strategy used in AKIKI (now termed “standard”) with another in which RRT is further delayed for a longer period (termed “delayed strategy”). Methods/design: This is a prospective, multicenter, open-label, two-arm randomized trial. The study is composed of two stages (observational and randomization stages). At any time, the occurrence of a potentially severe condition (severe hyperkalemia, severe metabolic or mixed acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia) suggests immediate RRT initiation. Patients receiving (or who have received) intravenously administered catecholamines and/or invasive mechanical ventilation and presenting with AKI stage 3 of the KDIGO classification and with no potentially severe condition are included in the observational stage. Patients presenting a serum urea concentration > 40 mmol/l and/or an oliguria/anuria for more than 72 h are randomly allocated to a standard (RRT is initiated within 12 h) or a delayed RRT strategy (RRT is initiated only if an above-mentioned potentially severe condition occurs or if the serum urea concentration reaches 50 mmol/l). The primary outcome will be the number of RRT-free days at day 28. One interim analysis is planned. It is expected to include 810 patients in the observational stage and to randomize 270 subjects. Discussion: The AKIKI2 study should improve the knowledge of RRT initiation criteria in critically ill patients. The potential reduction in RRT use allowed by a delayed RRT strategy might be associated with less invasive care and decreased costs. Enrollment is ongoing. Inclusions are expected to be completed by November 2019. Trial registration: ClinicalTrials.gov, ID: NCT03396757. Registered on 11 January 2018.
- Open Access
- 1 January 2019
- Published by Elsevier in Annals of Intensive Care
- Vol. 9 (1) , 2-10
Long-term health-related quality of life of critically ill patients with haematological malignancies: a prospective observational multicenter study
- 1 January 2019
- Published by Elsevier in Annals of Intensive Care
- Vol. 9 (1) , 2-10
Open AccessLong-term health-related quality of life of critically ill patients with haematological malignancies: a prospective observational multicenter study